Levetiracetam and valproate sodium both reduce seizures when added to lamotrigine, but levetiracetam has fewer side effects.
5 citations
,
January 2022 in “Asian Pacific Journal of Cancer Prevention” Certain VDR gene changes can affect melanoma risk.
13 citations
,
January 2017 in “Annals of dermatology/Annals of Dermatology” Simvastatin/ezetimibe may help some patients with severe alopecia areata regrow hair.
January 2026 in “JAAD International” Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” 36 citations
,
October 2008 in “European journal of paediatric neurology” Valproic acid treatment may cause temporary hair loss due to reduced zinc and biotinidase levels, which tend to normalize after 6 months.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
13 citations
,
September 2022 in “International Journal of Molecular Sciences” Five existing drugs may help fight Swine Acute Diarrhea Syndrome Coronavirus.
January 2011 in “Arqueología, historia y viajes sobre el mundo medieval/Arqueología, historia y viajes sobre el mundo medieval” Sodium valproate can cause severe liver disease and side effects, sometimes leading to death.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
10 citations
,
November 2019 in “American Journal of Tropical Medicine and Hygiene” Overdosing on veterinary albendazole can cause severe health issues like hair loss and low blood cell count.
April 2023 in “Journal of Investigative Dermatology” Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
Baricitinib effectively regrows hair in severe alopecia areata cases.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical Vorinostat shows promise for treating alopecia areata by promoting hair regrowth.
21 citations
,
June 2011 in “Journal of child neurology” Valproic acid and carbamazepine do not change biotin or biotinidase levels but may lower zinc levels, still within normal range.
1 citations
,
September 2025 in “PLoS ONE” Certain drugs may cause vitiligo, so patients should be monitored.
October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.
1 citations
,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology” 2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib is a safe and effective treatment for severe alopecia areata.
1 citations
,
June 2022 in “JAMA” Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
4 citations
,
October 2013 in “PLoS ONE” Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.
4 citations
,
May 2025 in “Dermatology and Therapy” Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
January 2004 in “Headache” Divalproex sodium significantly improved headaches in two-thirds of patients.
November 2023 in “Children” Many pediatric epilepsy patients experience preventable severe adverse drug reactions, especially with certain medications and risk factors.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
8 citations
,
April 2022 in “International Journal of Environmental Research and Public Health” Most children with epilepsy on antiepileptic drugs experience side effects, especially those on multiple drugs, but these drugs help reduce seizures.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”